We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Efficacy of the Priority Review Voucher Program

David B. Ridley, PhD1; Jennifer Dent, MBA2; Christopher Egerton-Warburton, MA3
[+] Author Affiliations
1Duke University, Durham, North Carolina
2BIO Ventures for Global Health, Seattle, Washington
3Lion’s Head Global Partners, London, United Kingdom
JAMA. 2016;315(15):1659-1660. doi:10.1001/jama.2016.0377.
Text Size: A A A
Published online


To the Editor Dr Kesselheim and colleagues1 assessed the priority review voucher program, which rewards companies for US Food and Drug Administration (FDA) registration of treatments for rare pediatric or neglected diseases. We have a more optimistic view of the program.

First, the authors wrote that “several more promising approaches exist,” including public funding of “basic science research.” Although funding from the National Institutes of Health (NIH) is important for basic science, the NIH rarely funds late-stage product development. Additional incentives, like the priority review voucher, are needed to advance drugs through approval. The voucher program does not preclude other mechanisms because public funds are not used.2 The FDA charges a user fee (currently $2.7 million) to offset the cost of the program.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




April 19, 2016
Ameet Sarpatwari, JD, PhD; Aaron S. Kesselheim, MD, JD, MPH
1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2016;315(15):1660-1661. doi:10.1001/jama.2016.0386.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...